What does this research mean for the field?

Cefiderocol demonstrates potent bactericidal efficacy against carbapenem-resistant Gram-negative bacilli in respiratory tract infections when administered via a prolonged 3-hour infusion that optimizes time above the minimum inhibitory concentration. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To evaluate cefiderocol's effectiveness against carbapenem-resistant gram-negative bacilli in a rat model.

June 20, 2017Antimicrobial Agents and ChemotherapyOpen Access

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics

View Full Paper

Ask AI

Bookmark

Authors

SMShuhei MatsumotoUniversity of Tokyo Hospital CSChristine M. SingleyGlaxoSmithKline (United States)JHJennifer L. HooverGlaxoSmithKline (United States)

Discussion

Member takes

Implication

Randomized trial evaluates cefiderocol's efficacy in carbapenem-resistant infections in rats, suggesting treatment potential.

Key Points

To evaluate cefiderocol's effectiveness against carbapenem-resistant gram-negative bacilli in a rat model.
Used immunocompetent rat respiratory tract infection models recreating human plasma pharmacokinetics.
Administered cefiderocol at 2 g every 8 hours as a 3-hour infusion for 4 days.
Assessed 6 clinical isolates of gram-negative bacilli, including P. aeruginosa, A. baumannii, and K. pneumoniae.
Cefiderocol produced a >3 log10 reduction in viable cells of carbapenem-resistant isolates.
Bactericidal activity was noted against all tested isolates when the infusion time was set to 1 hour.
Higher efficacy correlated with increased % fT MIC for cefiderocol compared to the 1-hour infusion.

Cite This Study

Matsumoto et al. (2017) studied this question.

synapsesocial.com/papers/6a62ec8f6a6e856b79094313 https://doi.org/10.1128/aac.00700-17

View Full Paper

Ask AI

Bookmark

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider